New weight loss pill beats oral Ozempic in major trial

Data ReadoutpositiveorforglipronsemaglutideOzempicPositive

AI Analysis

Summary

Orforglipron, a once-daily oral weight-loss pill, demonstrated superior efficacy compared to oral semaglutide in a major clinical trial, with additional benefits of no refrigeration requirements and lower manufacturing costs.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

orforglipron demonstrated superior weight loss and blood sugar improvements compared to oral semaglutide

Importance:7/10

Sentiment:

0.80

weight lossGLP-1 agonistoral formulationclinical trialcompetitor comparison

Related Companies

$BTTX $DMII

Read the original article

Published by ScienceDaily Pharmaceuticals on July 8, 2026 5:16 AM

Read Original